47 research outputs found
12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
Get PDF
Performance of the autoinflammatory disease damage index (ADDI) in patients with CAPS, TRAPS, HIDS and FMF
No full textLocal and systemic reaction to meningococcal vaccination in a patient with Cryopyrin-associated Periodic Syndrome
No full textDeterminants of health-related quality of life in children and adults with autoinflammatory diseases
No full textRecommendations for collaborative paediatric research including biobanking in Europe - A Single HUB and Access Point for Paediatric Rheumatology in Europe (SHARE) Initiative
No full text
Conjoint Methodology Used to Assess Patient preferences in Cryopyrin-associated autoinflammatory syndrome (CAPS)
No full textLangzeitwirksamkeit und Sicherheit von Canakinumab bei Patienten mit HIDS (Hyper-IgD-Syndrom) - Interimsanalyse des RELIANCE-Registers
No full text
